Literature DB >> 8074213

Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism.

D A Fryburg1.   

Abstract

The effect of a 6-h intra-arterial infusion of recombinant human (rh) insulin-like growth factor I (IGF-I) on forearm muscle metabolism was studied in 19 postabsorptive subjects. Forearm glucose, lactate, and phenylalanine (Phe) balances, as well as estimates of protein degradation (Phe Ra) and synthesis (Phe Rd) were measured before and at 3 and 6 h into an infusion of rhIGF-I at a dose of 1.8 (n = 6), 6.0 (n = 8), or 10.0 (n = 5) micrograms.kg-1.h-1. In response to intra-arterial IGF-I, deep venous IGF-I rose by 55, 141, and 315%, respectively (all P < 0.01), and forearm blood flow accelerated by 75 (1.8 microgram), 213 (6.0 micrograms), and 159% (10.0 micrograms; all P < 0.02). No change in forearm glucose uptake was observed at the lowest dose, whereas four- to sixfold increases were observed at both the 6 and 10 micrograms.kg-1.h-1 doses (both P < 0.02). Forearm Phe balance shifted positively at all three doses by 27 +/- 6, 48 +/- 7, and 51 +/- 9 nmol.min-1 x 100 ml-1, respectively (all P < 0.01). At all three doses, Phe Rd increased comparably by 49-74% (all P < 0.05). At the 6.0 and 10.0 but not the 1.8 microgram.kg-1.h-1 dose, Phe Ra decreased by approximately 45% (P < 0.02). Forearm muscle metabolism was also studied in the contralateral non-IGF-infused arm at these three doses. Despite increases in deep venous IGF-I up to 517 ng/ml due to recirculating IGF-I (10.0 micrograms.kg-1.h-1 dose), contralateral forearm muscle glucose, lactate, or Phe handling did not change. In conclusion, intra-arterial IGF-I exhibits growth hormone-like effects at all doses tested, whereas the insulin-like effects are observed at higher doses; these effects appear dependent on the route of administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074213     DOI: 10.1152/ajpendo.1994.267.2.E331

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  22 in total

1.  GH/IGF-I axis in severe systemic disorders.

Authors:  P De Feo
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

2.  Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease.

Authors:  M A McNurlan; P J Garlick; R T Steigbigel; K A DeCristofaro; R A Frost; C H Lang; R W Johnson; A M Santasier; C J Cabahug; J Fuhrer; M C Gelato
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 3.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

4.  Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients.

Authors:  G Garibotto; A Barreca; R Russo; A Sofia; P Araghi; A Cesarone; M Malaspina; F Fiorini; F Minuto; A Tizianello
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

Review 5.  Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature.

Authors:  Eugene J Barrett; Hong Wang; Charles T Upchurch; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-24       Impact factor: 4.310

Review 6.  Insulin-like growth factor I: an attractive option for chronic heart failure?

Authors:  M Y Donath; J Zapf
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 3.923

Review 7.  Emerging drugs for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Jerry R Mendell
Journal:  Expert Opin Emerg Drugs       Date:  2012-06       Impact factor: 4.191

8.  Effects of growth hormone and insulin-like growth factor-1 on postoperative muscle and substrate metabolism.

Authors:  Folke Hammarqvist; Ingmar Wennström; Jan Wernerman
Journal:  J Nutr Metab       Date:  2009-11-22

9.  Regulation of IRS1/Akt insulin signaling by microRNA-128a during myogenesis.

Authors:  Norio Motohashi; Matthew S Alexander; Yuko Shimizu-Motohashi; Jennifer A Myers; Genri Kawahara; Louis M Kunkel
Journal:  J Cell Sci       Date:  2013-04-19       Impact factor: 5.285

Review 10.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.